Novartis Institutes for Biomedical Research (NIBR) Oncology, Novartis, Basel, Switzerland.
Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sci Rep. 2020 Nov 18;10(1):20044. doi: 10.1038/s41598-020-76960-z.
MYC oncoprotein is a multifunctional transcription factor that regulates the expression of a large number of genes involved in cellular growth, proliferation and metabolism. Altered MYC protein level lead to cellular transformation and tumorigenesis. MYC is deregulated in > 50% of human cancers, rendering it an attractive drug target. However, direct inhibition of this class of proteins using conventional small molecules is challenging due to their intrinsically disordered state. To discover novel posttranslational regulators of MYC protein stability and turnover, we established a genetic screen in mammalian cells by combining a fluorescent protein-based MYC abundance sensor, CRISPR/Cas9-based gene knockouts and next-generation sequencing. Our screen identifies UBR5, an E3 ligase of the HECT-type family, as a novel regulator of MYC degradation. Even in the presence of the well-described and functional MYC ligase, FBXW7, UBR5 depletion leads to accumulation of MYC in cells. We demonstrate interaction of UBR5 with MYC and reduced K48-linked ubiquitination of MYC upon loss of UBR5 in cells. Interestingly, in cancer cell lines with amplified MYC expression, depletion of UBR5 resulted in reduced cell survival, as a consequence of MYC stabilization. Finally, we show that MYC and UBR5 are co-amplified in more than 40% of cancer cells and that MYC copy number amplification correlates with enhanced transcriptional output of UBR5. This suggests that UBR5 acts as a buffer in MYC amplified settings and protects these cells from apoptosis.
MYC 癌蛋白是一种多功能转录因子,可调节参与细胞生长、增殖和代谢的大量基因的表达。MYC 蛋白水平的改变导致细胞转化和肿瘤发生。在超过 50%的人类癌症中,MYC 被失调,使其成为一个有吸引力的药物靶点。然而,由于其固有无序状态,使用常规小分子直接抑制此类蛋白质具有挑战性。为了发现 MYC 蛋白稳定性和周转率的新型翻译后调节因子,我们通过将基于荧光蛋白的 MYC 丰度传感器、基于 CRISPR/Cas9 的基因敲除和下一代测序相结合,在哺乳动物细胞中建立了一个遗传筛选。我们的筛选确定了 UBR5,一种 HECT 型家族的 E3 连接酶,作为 MYC 降解的新型调节因子。即使在存在描述良好且功能正常的 MYC 连接酶 FBXW7 的情况下,UBR5 的缺失也会导致细胞中 MYC 的积累。我们证明了 UBR5 与 MYC 的相互作用以及细胞中 UBR5 缺失时 MYC 上 K48 连接的泛素化减少。有趣的是,在 MYC 表达扩增的癌细胞系中,UBR5 的缺失导致细胞存活减少,这是由于 MYC 稳定。最后,我们表明在超过 40%的癌细胞中 MYC 和 UBR5 被共扩增,并且 MYC 拷贝数扩增与 UBR5 的转录输出增强相关。这表明 UBR5 在 MYC 扩增的情况下充当缓冲液,并保护这些细胞免于凋亡。